corticotropin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
corticosteroids, except prednisolone derivatives 4931 9002-60-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • corticotropin
  • ACTH
  • corticotrophin
  • adrenocorticotrophic hormone
  • acthar gel
  • cortrophin
  • corticotropin zinc hydroxide
  • corticotropin-zinc hydroxide
  • cortrophin-zinc
A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress.
  • Molecular weight: 4541.14
  • Formula: C207H308N56O58S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 114
  • HDO: 63
  • TPSA: 1836.25
  • ALOGS:
  • ROTB: 145

Drug dosage:

DoseUnitRoute
25 U P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 3, 1950 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 353.68 19.25 289 10817 291398 90325943
Multiple sclerosis relapse 259.34 19.25 127 10979 52178 90565163
Injection site bruising 250.38 19.25 124 10982 52183 90565158
Blood glucose increased 137.73 19.25 105 11001 95141 90522200
Contraindicated product administered 120.76 19.25 171 10935 319968 90297373
Abnormal weight gain 105.98 19.25 30 11076 2635 90614706
Swelling face 105.25 19.25 84 11022 81268 90536073
Blood pressure increased 81.20 19.25 110 10996 197107 90420234
Insomnia 79.99 19.25 145 10961 333329 90284012
Diffuse large B-cell lymphoma refractory 79.50 19.25 22 11084 1778 90615563
Injection site pruritus 74.80 19.25 58 11048 53776 90563565
Fluid retention 69.94 19.25 69 11037 88022 90529319
Therapy cessation 63.59 19.25 45 11061 36316 90581025
Magnetic resonance imaging head abnormal 63.46 19.25 20 11086 2536 90614805
Peripheral swelling 60.75 19.25 147 10959 412959 90204382
Cushingoid 59.83 19.25 28 11078 10367 90606974
Increased appetite 56.53 19.25 28 11078 11737 90605604
Injection site discolouration 53.32 19.25 25 11081 9295 90608046
Irritability 52.99 19.25 40 11066 35622 90581719
Illness 52.10 19.25 57 11049 81912 90535429
Hospitalisation 51.99 19.25 71 11035 128029 90489312
Weight increased 48.36 19.25 136 10970 417791 90199550
Skin hyperpigmentation 47.47 19.25 21 11085 6830 90610511
COVID-19 46.35 19.25 78 11028 168765 90448576
Injection site pain 46.04 19.25 79 11027 173620 90443721
Injection site erythema 45.21 19.25 58 11048 98444 90518897
Infantile spasms 42.18 19.25 9 11097 241 90617100
Death 40.15 19.25 135 10971 456416 90160925
Surgery 37.17 19.25 36 11070 44851 90572490
Infusion related reaction 36.99 19.25 4 11102 416776 90200565
Feeling abnormal 36.59 19.25 70 11036 167165 90450176
Epidural lipomatosis 36.27 19.25 8 11098 251 90617090
Off label use 34.72 19.25 51 11055 1102201 89515140
Headache 33.63 19.25 200 10906 862546 89754795
Drug intolerance 33.54 19.25 7 11099 447584 90169757
Maternal exposure during pregnancy 33.14 19.25 3 11103 360060 90257281
Condition aggravated 30.59 19.25 149 10957 595396 90021945
Injection site swelling 30.26 19.25 37 11069 59802 90557539
Cytokine release syndrome 30.13 19.25 26 11080 27947 90589394
Hepatic enzyme increased 28.38 19.25 5 11101 360731 90256610
Eye operation 27.84 19.25 11 11095 2698 90614643
General physical health deterioration 27.77 19.25 5 11101 355110 90262231
Vision blurred 27.68 19.25 49 11057 110244 90507097
Mood altered 27.18 19.25 20 11086 17124 90600217
Wound 26.63 19.25 3 11103 302977 90314364
Polymyositis 26.50 19.25 10 11096 2169 90615172
Injection site haemorrhage 25.90 19.25 24 11082 28294 90589047
Renal disorder 25.22 19.25 27 11079 37832 90579509
Heart rate increased 24.36 19.25 47 11059 112855 90504486
Seizure 24.18 19.25 56 11050 152573 90464768
Sarcoidosis 22.91 19.25 15 11091 10658 90606683
Injection site discharge 22.63 19.25 8 11098 1443 90615898
Gait disturbance 21.94 19.25 76 11030 260420 90356921
Drug hypersensitivity 21.92 19.25 15 11091 463594 90153747
Nail pigmentation 20.61 19.25 5 11101 240 90617101
Acne 20.17 19.25 21 11085 28486 90588855
Appetite disorder 20.01 19.25 13 11093 9120 90608221
Exposure during pregnancy 19.42 19.25 3 11103 238407 90378934
Visual impairment 19.27 19.25 47 11059 132318 90485023

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Contraindicated product administered 231.66 26.02 90 4335 25182 42591728
Product dose omission issue 122.84 26.02 112 4313 154253 42462657
Diffuse large B-cell lymphoma refractory 119.55 26.02 30 4395 1967 42614943
Infantile spasms 104.37 26.02 19 4406 259 42616651
Blood glucose increased 97.53 26.02 72 4353 73627 42543283
Insomnia 82.74 26.02 80 4345 118173 42498737
Injection site bruising 77.78 26.02 33 4392 11492 42605418
Fluid retention 68.51 26.02 42 4383 31577 42585333
Drug ineffective 67.04 26.02 178 4247 630019 41986891
Cytokine release syndrome 59.94 26.02 44 4381 44483 42572427
Peripheral swelling 59.20 26.02 59 4366 90211 42526699
Hospitalisation 55.15 26.02 52 4373 74278 42542632
Magnetic resonance imaging head abnormal 53.05 26.02 15 4410 1552 42615358
Irritability 47.63 26.02 32 4393 28096 42588814
Multiple sclerosis relapse 47.20 26.02 25 4400 14239 42602671
Weight increased 47.14 26.02 57 4368 107926 42508984
Abnormal weight gain 46.44 26.02 13 4412 1297 42615613
Multiple-drug resistance 42.95 26.02 19 4406 7303 42609607
Blood pressure increased 39.97 26.02 51 4374 101877 42515033
Benign cardiac neoplasm 36.57 26.02 6 4419 42 42616868
Injection site pruritus 35.47 26.02 18 4407 9387 42607523
Increased appetite 33.45 26.02 17 4408 8889 42608021
Swelling 32.52 26.02 34 4391 54851 42562059
Astrocytoma, low grade 31.71 26.02 6 4419 102 42616808
Cushingoid 30.61 26.02 12 4413 3410 42613500
Intramyelinic oedema 29.03 26.02 4 4421 6 42616904
Hypertension 27.12 26.02 56 4369 167148 42449762
Tuberous sclerosis complex 26.77 26.02 5 4420 79 42616831

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Contraindicated product administered 308.74 20.58 229 10712 248038 110330320
Product dose omission issue 301.34 20.58 251 10690 321531 110256827
Diffuse large B-cell lymphoma refractory 231.40 20.58 53 10888 2468 110575890
Injection site bruising 194.71 20.58 97 10844 51166 110527192
Blood glucose increased 159.34 20.58 120 10821 132376 110445982
Multiple sclerosis relapse 158.75 20.58 84 10857 50156 110528202
Magnetic resonance imaging head abnormal 112.92 20.58 32 10909 3503 110574855
Cytokine release syndrome 105.77 20.58 73 10868 70233 110508125
Abnormal weight gain 103.48 20.58 30 10911 3561 110574797
Insomnia 98.83 20.58 148 10793 360442 110217916
Infantile spasms 86.51 20.58 17 10924 374 110577984
Injection site pruritus 86.11 20.58 57 10884 51201 110527157
Fluid retention 82.59 20.58 71 10870 94236 110484122
Blood pressure increased 80.86 20.58 113 10828 258260 110320098
Irritability 79.91 20.58 53 10888 47756 110530602
Peripheral swelling 74.66 20.58 139 10802 403895 110174463
Cushingoid 72.09 20.58 31 10910 11681 110566677
Swelling face 71.83 20.58 65 10876 92256 110486102
Therapy cessation 66.09 20.58 46 10895 44811 110533547
Weight increased 54.61 20.58 125 10816 419519 110158839
Injection site erythema 50.29 20.58 54 10887 94122 110484236
Increased appetite 47.15 20.58 25 10916 14952 110563406
Drug ineffective 47.09 20.58 283 10658 1520257 109058101
Injection site pain 42.98 20.58 69 10872 177853 110400505
Skin hyperpigmentation 37.61 20.58 18 10923 8678 110569680
Benign cardiac neoplasm 36.86 20.58 6 10935 42 110578316
Multiple-drug resistance 33.15 20.58 19 10922 13216 110565142
Vision blurred 32.47 20.58 51 10890 128971 110449387
Surgery 31.96 20.58 29 10912 41254 110537104
Death 31.79 20.58 145 10796 698724 109879634
Injection site discolouration 30.95 20.58 16 10925 9087 110569271
Astrocytoma, low grade 30.93 20.58 6 10935 123 110578235
Product administration interrupted 30.41 20.58 17 10924 11275 110567083
Intramyelinic oedema 28.84 20.58 4 10937 7 110578351
Diffuse large B-cell lymphoma 27.46 20.58 18 10923 15880 110562478
Hospitalisation 27.46 20.58 50 10891 142443 110435915
Eye operation 26.62 20.58 10 10931 2657 110575701
Feeling abnormal 25.88 20.58 56 10885 180655 110397703
Injection site haemorrhage 25.17 20.58 23 10918 33005 110545353
Drug intolerance 24.85 20.58 5 10936 406507 110171851
Fatigue 24.36 20.58 204 10737 1215754 109362604
Tuberous sclerosis complex 24.25 20.58 5 10936 141 110578217
Hypertension 24.03 20.58 107 10834 509977 110068381
Gait disturbance 23.89 20.58 71 10870 278137 110300221
Blood potassium decreased 23.70 20.58 28 10913 54086 110524272
Sarcoidosis 23.59 20.58 15 10926 12564 110565794
Visual impairment 23.20 20.58 45 10896 134383 110443975
Thrombocytopenia 21.94 20.58 4 10937 348881 110229477
Epidural lipomatosis 21.54 20.58 8 10933 2059 110576299
Headache 21.50 20.58 155 10786 882222 109696136
Immune effector cell-associated neurotoxicity syndrome 21.39 20.58 15 10926 14767 110563591
Heart rate increased 21.08 20.58 45 10896 143789 110434569
General physical health deterioration 20.85 20.58 8 10933 425287 110153071

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01AA01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
ACTH
FDA CS M0000499 Adrenocorticotropic Hormone
CHEBI has role CHEBI:33295 diagnostic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:76595 nephroprotective agent
CHEBI has role CHEBI:231911 renoprotective agent
FDA EPC N0000175941 Adrenocorticotropic Hormone

Related Drugs by ATC class:

H01AA ACTH 1 drug
tetracosactide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
West syndrome indication 28055006
Stevens-Johnson syndrome indication 73442001 DOID:0050426
Exacerbation of multiple sclerosis indication 192929006




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Stimulation of the adrenal cortex where there is a general deficiency of ACTH Indication
Cattle Stimulation of the adrenal cortex where there is a general deficiency of ACTH Indication
Cattle Primary bovine ketosis Indication
Dogs Diagnostic aid to test for adrenal dysfunction Indication
Dogs Stimulation of the adrenal cortex where there is a general deficiency of ACTH Indication

🐶 Veterinary products

ProductApplicantIngredients
Adrenomone Dechra, Ltd. 1
ACTH Gel Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.15 acidic
pKa2 3.37 acidic
pKa3 3.62 acidic
pKa4 3.86 acidic
pKa5 4.07 acidic
pKa6 4.31 acidic
pKa7 4.6 acidic
pKa8 9.43 acidic
pKa9 10.05 acidic
pKa10 12.25 acidic
pKa11 12.36 acidic
pKa12 12.63 acidic
pKa13 12.69 acidic
pKa14 12.93 acidic
pKa15 13.11 acidic
pKa16 13.11 acidic
pKa17 13.22 acidic
pKa18 13.41 acidic
pKa19 13.55 acidic
pKa20 13.6 acidic
pKa21 13.66 acidic
pKa22 13.75 acidic
pKa23 13.76 acidic
pKa24 13.79 acidic
pKa25 13.89 acidic
pKa26 14.0 acidic
pKa27 11.5 Basic
pKa28 11.26 Basic
pKa29 11.01 Basic
pKa30 10.81 Basic
pKa31 10.55 Basic
pKa32 10.3 Basic
pKa33 9.94 Basic
pKa34 7.62 Basic
pKa35 6.69 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
40 UNITS/0.5ML ACTHAR GEL (AUTOINJECTOR) MALLINCKRODT IRELAND N008372 Feb. 29, 2024 RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
40 UNITS/0.5ML ACTHAR GEL (AUTOINJECTOR) MALLINCKRODT IRELAND N008372 Feb. 29, 2024 RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
40 UNITS/0.5ML ACTHAR GEL (AUTOINJECTOR) MALLINCKRODT IRELAND N008372 Feb. 29, 2024 RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
80 UNITS/ML ACTHAR GEL MALLINCKRODT IRELAND N008372 None RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
80 UNITS/ML ACTHAR GEL (AUTOINJECTOR) MALLINCKRODT IRELAND N008372 Feb. 29, 2024 RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
80 UNITS/ML ACTHAR GEL MALLINCKRODT IRELAND N008372 None RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
80 UNITS/ML ACTHAR GEL (AUTOINJECTOR) MALLINCKRODT IRELAND N008372 Feb. 29, 2024 RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
80 UNITS/ML ACTHAR GEL MALLINCKRODT IRELAND N008372 None RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
80 UNITS/ML ACTHAR GEL (AUTOINJECTOR) MALLINCKRODT IRELAND N008372 Feb. 29, 2024 RX INJECTABLE INJECTION 11752199 July 18, 2041 TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 ALLERGIC CONJUNCTIVITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 ANTERIOR SEGMENT INFLAMMATION
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 ATOPIC DERMATITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 CHORIORETINITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 IRIDOCYCLITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 IRITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 KERATITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 OPTIC NEURITIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 SERUM SICKNESS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 SEVERE PSORIASIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 SYMPTOMATIC SARCOIDOSIS
40 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None DISCN INJECTABLE INJECTION 12102662 Oct. 27, 2043 TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 ALLERGIC CONJUNCTIVITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 ANTERIOR SEGMENT INFLAMMATION
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 ATOPIC DERMATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 CHORIORETINITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 IRIDOCYCLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 IRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 KERATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 OPTIC NEURITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 SERUM SICKNESS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 SEVERE PSORIASIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 SYMPTOMATIC SARCOIDOSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 11975047 Oct. 27, 2043 TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 ALLERGIC CONJUNCTIVITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 ANTERIOR SEGMENT INFLAMMATION
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 ATOPIC DERMATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 CHORIORETINITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 IRIDOCYCLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 IRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 KERATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 OPTIC NEURITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 SERUM SICKNESS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 SEVERE PSORIASIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 SYMPTOMATIC SARCOIDOSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12102662 Oct. 27, 2043 TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 ALLERGIC CONJUNCTIVITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 ANTERIOR SEGMENT INFLAMMATION
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 ATOPIC DERMATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 CHORIORETINITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 IRIDOCYCLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 IRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 KERATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 OPTIC NEURITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 SERUM SICKNESS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 SEVERE PSORIASIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 SYMPTOMATIC SARCOIDOSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12233105 Oct. 27, 2043 TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 ALLERGIC CONJUNCTIVITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 ANTERIOR SEGMENT INFLAMMATION
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 ATOPIC DERMATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 CHORIORETINITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 IRIDOCYCLITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 IRITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 KERATITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 OPTIC NEURITIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 SERUM SICKNESS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 SEVERE PSORIASIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 SYMPTOMATIC SARCOIDOSIS
80 UNITS/ML PURIFIED CORTROPHIN GEL ANI PHARMS N008975 None RX INJECTABLE INJECTION 12440542 Oct. 27, 2043 TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Adrenocorticotropic hormone receptor GPCR AGONIST UNKNOWN IUPHAR
Melanocortin receptor 4 GPCR AGONIST Ki 6.16 IUPHAR
Melanocortin receptor 3 GPCR AGONIST Ki 7.06 IUPHAR
Melanocyte-stimulating hormone receptor GPCR AGONIST Ki 8.60 IUPHAR
Adrenocorticotropic hormone receptor GPCR AGONIST Kd 9.80 IUPHAR

External reference:

IDSource
D00146 KEGG_DRUG
4018523 VUID
N0000146845 NUI
12427-33-7 SECONDARY_CAS_RN
4018523 VANDF
4022410 VANDF
CHEBI:3892 CHEBI
CHEMBL1201610 ChEMBL_ID
9050-75-3 SECONDARY_CAS_RN
DB01285 DRUGBANK_ID
2584471 RXNORM
2492 MMSL
326050 MMSL
4506 MMSL
4507 MMSL
84 MMSL
d00604 MMSL
002113 NDDF
002114 NDDF
126187000 SNOMEDCT_US
40789008 SNOMEDCT_US
C0001655 UMLSCUI
CHEMBL1201609 ChEMBL_ID
1366 INN_ID
16132265 PUBCHEM_CID
3633 IUPHAR_LIGAND_ID
K0U68Q2TXA UNII
471 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
1 Detoxification HUMAN OTC DRUG LABEL 81 55146-011 LIQUID 30 [hp_C] ORAL unapproved homeopathic 9 sections
Purified Cortrophin Gel HUMAN PRESCRIPTION DRUG LABEL 1 62559-860 INJECTION 80 [USPU] INTRAMUSCULAR NDA 15 sections
Purified Cortrophin Gel HUMAN PRESCRIPTION DRUG LABEL 1 62559-861 INJECTION 80 [USPU] SUBCUTANEOUS NDA 15 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8710 INJECTION 80 [USPU] INTRAMUSCULAR NDA 29 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8710 INJECTION 80 [USPU] INTRAMUSCULAR NDA 29 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8711 INJECTION 80 [USPU] SUBCUTANEOUS NDA 29 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8711 INJECTION 80 [USPU] SUBCUTANEOUS NDA 29 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8712 INJECTION 40 [USPU] SUBCUTANEOUS NDA 29 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8712 INJECTION 40 [USPU] SUBCUTANEOUS NDA 29 sections